Faculty
Hematology Division
Alphabetical list (active faculty):   
Morey A. Blinder

Morey A. Blinder, MD

Professor

Department of Medicine

Hematology Division

Department of Pathology & Immunology

Clinical Interests

  • Disorders of iron metabolism
  • Sickle cell disease
  • Immune-mediated hematologic disease
  • Bleeding and thromboembolic disorders

Research Interests

  • Treatment of iron overload disorders and iron deficiency
  • Management of sickle cell disease
  • Treatment of ITP and TTP

Contact

  • 314-362-8814 (office)
  • 314-696-1391 (fax)
  • Hematology Division
    Mail Stop 8125-0022-01
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • Suite 1101 Wohl Hospital (office)

Research

My research focus is on the clinical treatment of patients with non-malignant hematologic disease. In particular, we have provided comprehensive care to a large cohort of adult patients with sickle cell disease as part of a funded Adult Hemoglobinopathy Treatment Center and have participated in several investigator-initiated and sponsored studies. For the treatment of sickle cell disease, one current focus is in further understanding the issues in transitioning from pediatric to adult care. Another focus is in the understanding and treatment of iron overload disorders with oral iron chelators. In addition to iron overload, I also have a longstanding interest in the diagnosis and treatment of iron deficiency anemia including the use of IV iron agents.

The second major clinical focus is the treatment of immune-mediated hematologic disease, most notably including ITP and TTP, with both newer regimens of immunosuppression as well as small molecules. We have participated in several clinical trials evaluating new approaches to the treatment of these diseases.

Lastly, my focus has been on the diagnosis and treatment of bleeding and thromboembolic disorders, including the participation in several multicenter studies for the treatment of venous thromboembolism. We have also recently established a Comprehensive Hemophilia Treatment Center including a multidisciplinary approach and are expanding our role in the hemophilia community.